Mirion Technologies, Inc. (MIR)

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2020	FY 2019
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019
Cancer Care Revenue	243.40M	237.00M	228.10M
Cancer Care Revenue Growth	2.70%	3.90%	5.65%
Other Medical Revenue	70.90M	73.80M	71.60M
Other Medical Revenue Growth	-3.93%	3.07%	4.37%
Total Medical Revenue	314.30M	310.80M	299.70M
Total Medical Revenue Growth	1.13%	3.70%	5.34%
Nuclear Revenue	416.20M	374.60M	316.60M
Nuclear Revenue Growth	11.11%	18.32%	8.50%
Labs and Research Revenue	123.70M	122.20M	131.70M
Labs and Research Revenue Growth	1.23%	-7.21%	7.16%
Other Nuclear & Safety Revenue	126.80M	117.80M	112.80M
Other Nuclear & Safety Revenue Growth	7.64%	4.43%	10.91%
Total Nuclear & Safety Revenue	666.70M	614.60M	561.10M
Total Nuclear & Safety Revenue Growth	8.48%	9.54%	8.66%
Revenue (Total)	981.00M	925.40M	860.80M
Revenue (Total) Growth	6.01%	7.51%	7.48%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2020	FY 2019
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019
North America Revenue	626.40M	582.20M	542.20M
North America Revenue Growth	7.59%	7.38%	5.84%
Europe Revenue	340.10M	327.60M	305.60M
Europe Revenue Growth	3.82%	7.20%	12.31%
Asia Pacific Revenue	14.50M	15.60M	13.00M
Asia Pacific Revenue Growth	-7.05%	20.00%	-21.21%
Revenue (Total)	981.00M	925.40M	860.80M
Revenue (Total) Growth	6.01%	7.51%	7.48%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2020	FY 2019
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019
Product Revenue	739.70M	690.60M	643.10M
Product Revenue Growth	7.11%	7.39%	7.58%
Service Revenue	241.30M	234.80M	217.70M
Service Revenue Growth	2.77%	7.85%	7.19%
Revenue (Total)	981.00M	925.40M	860.80M
Revenue (Total) Growth	6.01%	7.51%	7.48%

Adjusted EBITDA

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2020	FY 2019
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019
Medical Adjusted EBITDA	117.80M	116.40M	104.60M
Medical Adjusted EBITDA Growth	1.20%	11.28%	7.28%
Nuclear & Safety Adjusted EBITDA	185.30M	177.70M	159.80M
Nuclear & Safety Adjusted EBITDA Growth	4.28%	11.20%	18.02%
Corporate & Other Adjusted EBITDA	-67.60M	-66.20M	-60.80M
Operating Income (Total)	46.50M	51.50M	24.80M
Operating Income (Total) Growth	-9.71%	107.66%	-

EBIT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2020	FY 2019
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019
Medical Income from Operations	48.00M	46.90M	22.30M
Medical Income from Operations Growth	2.34%	110.31%	71.54%
Nuclear & Safety Income from Operations	100.30M	101.10M	78.90M
Nuclear & Safety Income from Operations Growth	-0.79%	28.14%	71.52%
Corporate & Other Income from Operations	-101.80M	-96.50M	-76.40M
Operating Income (Total)	46.50M	51.50M	24.80M
Operating Income (Total) Growth	-9.71%	107.66%	-

Capital Expenditures

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2020	FY 2019
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019
Medical Capital Expenditures	19.20M	20.20M	27.80M
Medical Capital Expenditures Growth	-4.95%	-27.34%	27.52%
Nuclear & Safety Capital Expenditures	20.00M	18.70M	17.70M
Nuclear & Safety Capital Expenditures Growth	6.95%	5.65%	-1.67%
Corporate & Other Capital Expenditures	1.00M	700.00K	3.30M
Corporate & Other Capital Expenditures Growth	42.86%	-78.79%	230.00%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2020	FY 2019
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019
Remaining Performance Obligations (RPO)	1.12B	1.10B	811.90M
Remaining Performance Obligations (RPO) Growth	1.48%	36.01%	-5.27%
Remaining Performance Obligations (RPO) to be Recognized Over NTM	36.00%	49.00%	54.00%
Order Book	1.12B	1.03B	843.00M
Order Book Growth	8.43%	22.42%	-7.26%
Medical - Organic Revenue Growth	-	3.10%	2.60%
Nuclear & Safety - Organic Revenue Growth	-	4.40%	8.80%
Total Organic Revenue Growth	-	3.90%	6.60%

Data Source: Fiscal.ai Last updated: Apr 29, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 15, 2026

Data Sources Report a data error